tagline 1996

December, 1996

• Congressional Battles Over Funding the Office of AIDS Research
  Broad, Brilliantly Coordinated Offensive Brings Sneaky Concession From Illinois' Rep. Porter
• Annus Mirabilis
  A Look Back at an Extraordinary Year for Basic and Clinical Research on AIDS -- and the Questions Raised
• Birmingham Bubble Burster
  Dr. Robert Schooley on HIV Eradication

November, 1996

• CPCRA v. Syntex
  Effect of ddI on Ganciclovir May Explain Disparity Between Two Prophylaxis Studies
• Clues to Non-Progressors
  Flurry of Discoveries in Multiple Labs Leads to Identification of HIV's Second Receptor -- And New Therapeutic Target
• TAG Debuts Its Wasting Report

October, 1996

• Recipes for Failure
  'Early' Is Right, They Say, Unless of Course Your Regimen's Wrong; Then You're Shit Out of Luck
• Caution, Flammable
  Smoldering Embers of HIV's 'Raging Fire,' Partly Doused, Threaten to Rekindle the Blaze
• Hitting it Early, Hard: The Aftermath
  The Fickle (and Unforgiving) Fashion of Antiretroviral Therapies: Early treatment choices and their unintended consequences

August/September, 1996

• Viral Load Comes of Age
  Propelled by Results from Multiple Studies, Viral Load Monitoring Lunges to the Forefront of HIV Medicine
• Aaron Diamond's Dynamic Duo: The Latest Word on Protease Resistance
  Treatment Activists Sit Down with Vancouver High Fliers, Try to Make Sense Out of the New Cries of 'Eureka'
• Resisitance Rules - Revised
  Amino acid substitutions conferring reduced sensitivity to selected protease inhibitors

July, 1996

• Threshold, Schmeshold
  Long-Awaited Research Paper Takes on the Viral Diversity Threshold, Cannibalistic CTLs and NSI-to-SI Switch
• Sacked on the Hill
  Licking Their Wounds Following a FY 1996 Budgetary Revocation, Activists Regroup for the Battle of 1997
• Random Gleanings
  Can HIV Be Eradicated from an Infected Individual?; The Seventy Percent Solution (a/k/a "Fools Rush In ..."); Nearly One Third Either Slow or Fast Progressors

June, 1996

• Clinically Clueless
  Keystone Group Addresses Crisis in Post-Marketing Treatment Research and Access to FDA-Approved Therapies
• Review and Reform
  OAR Advisory Panel Would Meld 12 Trials Networks into One and Requests Improved Institute Collaboration
• The Six Area Review Panels (ARPs)
  Of the NIH AIDS Research Program Evaluation Working Group of the Office of AIDS Research (OAR) Advisory Council (the "Levine Committee")

May, 1996

• Monitoring, Not Management
  Roche Requests Approval from FDA's Blood Products Committee for Its PCR Diagnostic - 7/10ths a log of 'noise'
• Deconstructing the Drama
  Former ACT UP/NY Scientific Wunderkind Denounces Movement As "Messianic Utopianism" - AIDS activism as religious cult
• Comparing Protease Combinations
  Reported maximum average reductions in plasma RNA with selected protease inhibitor combinations (in treament naive/experienced* individuals)
• Random Gleanings
  A Tale of Two Epidemics; Researchers Report

April, 1996

• The Race to Ritonavir
  FDA Approves Second Protease Inhibitor in Record Time - As Abbott Chief Warns Many to "Wait for the data"
• Medications Contraindicated With the Use of Ritonavir
• Comparing the (RTI) Combinations
  Reported Maximum Average Reductions in Plasma HIV RNA with Selected RTI Combination Regimens (in Treatment Naive Individuals)
• Azithro v. Clarithro
  Two Drugs Might Be Better Than One for Prophylaxis of M. Avium Disease, But Are Any of Them Clarithromycin?
• Random Gleanings
  Expanded Access for Nevirapine and Delavirdine; OAR Loses Out on 1996 Budgetary Authority; Lowering the Vaccine Goalpost

March, 1996

• White House Summit
  Clinton, Shalala, Fleming Host Gathering of AIDS Advocates, Care Givers and People Living with HIV at Day-Long Conference
• Resistance Rules
  Amino acid substitutions conferring reduced sensitivity to selected protease inhibitors
• Retroviral Reprise
  Confab's Clarion Call: "Get It Down and Keep It Down," with Hints—And Only Hints—Of How To Get There
• Random Gleanings
  Message from CPCRA 007 and other combination studies; AZT resistant virus more virulent than wild-type?

February, 1996

• Hasta la vista, ACTG!
  ACTG Oncology Committee Finds New Home at National Cancer Institute, But Funding Is Woefully Inadequate - Six studies slated
• Mother Pataki's Cupboard
  AIDS Therapeutics Omitted from the NY State ADAP Formulary as of 1/96
• Shakedown
  Federal Budget Shutdown and Flood of New Approvals Combine to Threaten Access to FDA-Approved AIDS Drugs